Macrocyclic Tetrapeptide Analogues for Kappa Opioid Receptor Antagonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for CNS-related disorders such as schizophrenia, depression, and drug addiction often rely on small molecule kappa opioid receptor (KOR) antagonists with long duration of action, raising safety concerns, and lack peptide-based compounds with improved pharmacokinetic properties and specificity.
Innovation Solution
Development of macrocyclic tetrapeptide compounds, specifically those of Formula I, II, III, and IV, which are structurally distinct from typical opioid ligands, incorporating novel amino acid derivatives, providing improved physiochemical properties and specificity to KOR, thereby reducing off-target activities and potential side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If small molecule kappa opioid receptor antagonists are used for treating CNS-related disorders, then the duration of action is extended, but safety concerns increase due to prolonged receptor blockade
Solution Approach 1:
The patent changes the molecular parameters by transitioning from small molecule antagonists to macrocyclic tetrapeptide structures. This structural parameter change fundamentally alters the pharmacokinetic profile, providing prolonged duration of action through the stable macrocyclic structure while modifying receptor interaction characteristics to improve safety by reducing off-target effects associated with small molecule antagonists.
Solution Approach 2:
The invention employs composite peptide structures combining multiple amino acid residues (Phe, D-Pro, Phe, D-Trp) into a macrocyclic framework. This composite structure integrates both the pharmacophoric elements needed for KOR binding and the structural constraints that provide selective, prolonged antagonism with improved safety profile compared to small molecules.
2Reliability
If peptide-based compounds are developed to improve specificity to KOR, then off-target activities are reduced, but structural complexity increases compared to typical opioid ligands
Solution Approach 1:
The patent segments the opioid ligand structure into distinct amino acid components (Phe1, D-Pro2, Phe3, D-Trp4) that can be individually optimized. Each residue contributes specific functional properties: Phe for hydrophobic interactions, D-Pro for structural constraint and beta-turn formation, and D-Trp for aromatic stacking with receptor residues. This segmentation enables precise tuning of KOR specificity while managing structural complexity through modular design.
Solution Approach 2:
The invention applies local quality by assigning specific functional characteristics to different positions in the tetrapeptide sequence. The N-terminal Phe provides anchor binding, the D-Pro creates a rigid macrocyclic constraint, the Phe3 contributes to hydrophobic packing, and the C-terminal D-Trp engages in aromatic interactions with the receptor. This localized functional assignment maximizes KOR specificity while keeping the overall structure manageable.
Data Source
AI summary
The present technology provides compounds of Formula I (or pharmaceutically acceptable salts and/or solvates thereof) that are useful in treating a CNS-related disorder such as schizophrenia, schizoaffective disorder, migraine, depression, pain, drug addiction, drug use, and/or drug seeking behavior. Also provided are compositions, medicaments, and methods including such compounds.